Faes Farma is now receiving the long-awaited attention from investors

23/05/24 -"2023 earnings exceeded the street’s expectations and Faes is also off to a good start in 2024. In the near-to-medium term, growth should be driven by newer formulations of the firm’s key ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

23/05/24

Download

You may also be interested by these reports :

14/06/24

Idea Kicker

When we last teased Lundbeck’s (BUY; Denmark) story in May 2023, the share price had fiercely recovered (>45%) from the October 2022 lows, and the ...

12/06/24

BB Biotech

Portfolio news flow likely to support NAV growth in the medium term

12/06/24

Siegfried

Siegfried to acquire early-phase CDMO in the U.S., outlook reiterated

04/06/24

GSK plc

GSK lost c.9% (i.e. £6.2bn or $7.9bn) of its market cap yesterday after the Delaware (US) Court, in Zantac litigations, allowed the plaintiffs’ ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue